Xencor, Inc. Common Stock XNCR
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-14T01:47:26.900Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T21:00:01.938101698Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-14T01:47:25.747649+00:00
Xencor, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 32.67 | 106.6% | 13.8% | |||
| 25Δ | 33.68 | 105.3% | 11.6% | |||
| 30Δ | 40.59 | 103.2% | 11.9% | 34.69 | 104.1% | 9.5% |
| 35Δ | 39.52 | 102.0% | 9.9% | 35.52 | 105.2% | 8.2% |
| 40Δ | 38.80 | 106.2% | 9.0% | 36.28 | 107.3% | 7.4% |
| 45Δ | 38.08 | 110.5% | 8.2% | 37.03 | 109.4% | 6.6% |
| 50Δ | 37.35 | 114.7% | 7.3% | 37.78 | 111.5% | 5.8% |
| 55Δ | 36.63 | 119.0% | 6.4% | 38.54 | 113.6% | 5.0% |
| 60Δ | 35.90 | 123.2% | 5.6% | 39.29 | 115.7% | 4.2% |
| 65Δ | 35.18 | 127.4% | 4.7% | 40.06 | 117.5% | 3.4% |
| 70Δ | 34.24 | 127.7% | 3.9% | 41.09 | 115.3% | 2.9% |
| 75Δ | 33.22 | 126.6% | 3.2% | 42.12 | 113.1% | 2.3% |
| 80Δ | 32.21 | 125.5% | 2.4% | 43.14 | 110.8% | 1.7% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 32.67
- IV
- 106.6%
- B/E move
- 13.8%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 33.68
- IV
- 105.3%
- B/E move
- 11.6%
30Δ
- Pseudo strike
- 40.59
- IV
- 103.2%
- B/E move
- 11.9%
- Pseudo strike
- 34.69
- IV
- 104.1%
- B/E move
- 9.5%
35Δ
- Pseudo strike
- 39.52
- IV
- 102.0%
- B/E move
- 9.9%
- Pseudo strike
- 35.52
- IV
- 105.2%
- B/E move
- 8.2%
40Δ
- Pseudo strike
- 38.80
- IV
- 106.2%
- B/E move
- 9.0%
- Pseudo strike
- 36.28
- IV
- 107.3%
- B/E move
- 7.4%
45Δ
- Pseudo strike
- 38.08
- IV
- 110.5%
- B/E move
- 8.2%
- Pseudo strike
- 37.03
- IV
- 109.4%
- B/E move
- 6.6%
50Δ
- Pseudo strike
- 37.35
- IV
- 114.7%
- B/E move
- 7.3%
- Pseudo strike
- 37.78
- IV
- 111.5%
- B/E move
- 5.8%
55Δ
- Pseudo strike
- 36.63
- IV
- 119.0%
- B/E move
- 6.4%
- Pseudo strike
- 38.54
- IV
- 113.6%
- B/E move
- 5.0%
60Δ
- Pseudo strike
- 35.90
- IV
- 123.2%
- B/E move
- 5.6%
- Pseudo strike
- 39.29
- IV
- 115.7%
- B/E move
- 4.2%
65Δ
- Pseudo strike
- 35.18
- IV
- 127.4%
- B/E move
- 4.7%
- Pseudo strike
- 40.06
- IV
- 117.5%
- B/E move
- 3.4%
70Δ
- Pseudo strike
- 34.24
- IV
- 127.7%
- B/E move
- 3.9%
- Pseudo strike
- 41.09
- IV
- 115.3%
- B/E move
- 2.9%
75Δ
- Pseudo strike
- 33.22
- IV
- 126.6%
- B/E move
- 3.2%
- Pseudo strike
- 42.12
- IV
- 113.1%
- B/E move
- 2.3%
80Δ
- Pseudo strike
- 32.21
- IV
- 125.5%
- B/E move
- 2.4%
- Pseudo strike
- 43.14
- IV
- 110.8%
- B/E move
- 1.7%
Options history
Table
| Date | IV (%) |
|---|---|
| 113.18% | |
| 106.90% | |
| 104.50% | |
| 100.11% | |
| 103.01% | |
| 84.48% | |
| 87.11% | |
| 80.20% | |
| 82.27% | |
| 86.70% |
Biotechnology
ZBIO
Description unavailable
More →ZLAB
Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops and markets therapies to treat cancer, autoimmune and infectious diseases in China. The company is…
More →ZNTL
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment of various cancers.…
More →ZURA
Zura Bio Limited (Ticker: ZURA) is a biotechnology firm dedicated to developing breakthrough therapies for autoimmune disorders and rare diseases. The company features a diverse…
More →ZVRA
Description unavailable
More →ZYME
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in…
More →